Literature DB >> 29874375

Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.

Julia Kitz1, Emmanouil Fokas2, Tim Beissbarth3, Philipp Ströbel1, Christian Wittekind4, Arndt Hartmann5, Josef Rüschoff6, Thomas Papadopoulos7, Elisabeth Rösler8, Peter Ortloff-Kittredge8, Ulrich Kania9, Hans Schlitt10, Karl-Heinrich Link11, Wolf Bechstein12, Hans-Rudolf Raab13, Ludger Staib14, Christoph-Thomas Germer15, Torsten Liersch16, Rolf Sauer17, Claus Rödel2, Michael Ghadimi16, Werner Hohenberger18.   

Abstract

Importance: Previous retrospective studies have shown that surgical quality affects local control in rectal cancer.. Objective: In this secondary end point analysis, we evaluated the prognostic effect of the total mesorectal excision (TME) plane in the CAO/ARO/AIO-04 phase 3 randomized clinical trial. Design, Setting, and Participants: The CAO/ARO/AIO-04 trial enrolled 1236 patients with cT3-4 and/or node-positive rectal adenocarcinoma from 88 centers in Germany between July 25, 2006, and February 26, 2010. Interventions: Patients were randomized to receive treatment with standard fluorouracil-based preoperative chemoradiotherapy (CRT) alone (control arm) or oxaliplatin (experimental arm) followed by TME and adjuvant chemotherapy. Main Outcomes and Measures: The TME quality (mesorectal, intramesorectal, and muscularis propria plane) was prospectively assessed in 1152 operation specimens. An assessment was performed independently by pathologists and surgeons. The results were correlated with clinicopathologic data and the clinical outcome was tested, including multivariable analysis with the Cox regression model.
Results: Of 1152 German Caucasian participants, 332 (28.8) were women and the mean age was 63 years. The plane of TME was mesorectal in 930 patients (80.7%), intramesorectal in 169 (14.7%), and muscularis propria in 53 (4.6%). In a univariable analysis, the TME plane was significantly associated with 3-year disease-free survival (mesorectal vs intramesorectal vs muscularis propria, 95% CI, 73.1-78.8 vs 61.6-76.0 vs 55.6-81.3, respectively; P = .01), cumulative incidence of local and distant recurrences (mesorectal vs intramesorectal vs muscularis propria, 95% CI, 2.0-4.5 vs 1.2-8.1 vs 2.5-20.5, respectively; P < .001; and mesorectal vs intramesorectal vs muscularis propria, 95% CI, 17.0-22.4 vs 18.3-32.0 vs 14.2-39.0, respectively; P = .03, respectively), and overall survival (mesorectal vs intramesorectal vs muscularis propria, 95% CI, 88.3-92.3 vs 79.7-91.0 vs 81.6-98.7, respectively; P = .02). In contrast to the pathologist-based evaluation, the assessment of TME plane by the operating surgeon failed to demonstrate prognostic significance for any of these clinical end points. In a multivariable analysis, the plane of surgery (mesorectal vs muscularis propria TME) constituted an independent factor for local recurrence (P = .002). Conclusions and Relevance: This phase 3 randomized clinical trial confirms the long-term clinical effect of TME plane quality on local recurrence, as initially reported in the MRC CR07 study. The data highlight the key role of pathologists and surgeons in the multidisciplinary management of rectal cancer. Trial Registration: ClinicalTrials.gov Identifier: NCT00349076.

Entities:  

Mesh:

Year:  2018        PMID: 29874375      PMCID: PMC6142959          DOI: 10.1001/jamasurg.2018.1607

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  33 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.

Authors:  Joakim Folkesson; Helgi Birgisson; Lars Pahlman; Bjorn Cedermark; Bengt Glimelius; Ulf Gunnarsson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

Review 3.  Pathology is a necessary and informative tool in oncology clinical trials.

Authors:  Iris D Nagtegaal; Nicholas P West; J Han J M van Krieken; Phil Quirke
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

4.  Low rectal cancer: a call for a change of approach in abdominoperineal resection.

Authors:  Iris D Nagtegaal; Cornelius J H van de Velde; Corrie A M Marijnen; Jan H J M van Krieken; Philip Quirke
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

5.  Review of the quality of total mesorectal excision does not improve the prediction of outcome.

Authors:  P Demetter; A Jouret-Mourin; G Silversmit; T Vandendael; C Sempoux; A Hoorens; N Nagy; C Cuvelier; N Van Damme; F Penninckx
Journal:  Colorectal Dis       Date:  2016-09       Impact factor: 3.788

6.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

7.  Mesorectal grades predict recurrences after curative resection for rectal cancer.

Authors:  Sushil Maslekar; Abhiram Sharma; Alistair Macdonald; James Gunn; John R T Monson; John E Hartley
Journal:  Dis Colon Rectum       Date:  2007-02       Impact factor: 4.585

Review 8.  Advances and challenges in treatment of locally advanced rectal cancer.

Authors:  J Joshua Smith; Julio Garcia-Aguilar
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

9.  A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status.

Authors:  Christian Wittekind; Carolyn Compton; Phil Quirke; Iris Nagtegaal; Susanne Merkel; Paul Hermanek; Leslie H Sobin
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

Review 10.  Pathologic processing of the total mesorectal excision.

Authors:  Molly Campa-Thompson; Robert Weir; Natalie Calcetera; Philip Quirke; Susanne Carmack
Journal:  Clin Colon Rectal Surg       Date:  2015-03
View more
  27 in total

1.  College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.

Authors:  Hai-Yang Chen; Li-Li Feng; Ming Li; Huai-Qiang Ju; Yi Ding; Mei Lan; Shu-Mei Song; Wei-Dong Han; Li Yu; Ming-Biao Wei; Xiao-Lin Pang; Fang He; Shuai Liu; Jian Zheng; Yan Ma; Chu-Yang Lin; Ping Lan; Mei-Jin Huang; Yi-Feng Zou; Zu-Li Yang; Ting Wang; Jin-Yi Lang; Guy R Orangio; Vitaliy Poylin; Jaffer A Ajani; Wei-Hu Wang; Xiang-Bo Wan
Journal:  Oncologist       Date:  2021-02-22

Review 2.  [Evidence-based surgery of rectal cancer].

Authors:  M Grade; H Flebbe; B M Ghadimi
Journal:  Chirurg       Date:  2019-05       Impact factor: 0.955

3.  Oncologic results of conventional laparoscopic TME: is the intramesorectal plane really acceptable?

Authors:  A Martínez-Pérez; N de'Angelis
Journal:  Tech Coloproctol       Date:  2018-12-17       Impact factor: 3.781

4.  Does anastomotic leakage after rectal cancer resection worsen long-term oncologic outcome?

Authors:  Hiroshi Hasegawa; Takeru Matsuda; Akira Arimoto; Kimihiro Yamashita; Masayasu Nishi; Nobuhisa Takase; Masayoshi Hosono; Tetsu Nakamura; Satoshi Suzuki; Yoshihiro Kakeji
Journal:  Int J Colorectal Dis       Date:  2020-04-20       Impact factor: 2.571

5.  Short-term Outcomes of Laparoscopy-Assisted vs Open Surgery for Patients With Low Rectal Cancer: The LASRE Randomized Clinical Trial.

Authors:  Wei-Zhong Jiang; Jian-Min Xu; Jia-Di Xing; Hui-Zhong Qiu; Zi-Qiang Wang; Liang Kang; Hai-Jun Deng; Wei-Ping Chen; Qing-Tong Zhang; Xiao-Hui Du; Chun-Kang Yang; Yin-Cong Guo; Ming Zhong; Kai Ye; Jun You; Dong-Bo Xu; Xin-Xiang Li; Zhi-Guo Xiong; Kai-Xiong Tao; Ke-Feng Ding; Wei-Dong Zang; Yong Feng; Zhi-Zhong Pan; Ai-Wen Wu; Feng Huang; Ying Huang; Ye Wei; Xiang-Qian Su; Pan Chi
Journal:  JAMA Oncol       Date:  2022-09-15       Impact factor: 33.006

Review 6.  The multidisciplinary management of rectal cancer.

Authors:  Deborah S Keller; Mariana Berho; Rodrigo O Perez; Steven D Wexner; Manish Chand
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-12       Impact factor: 46.802

7.  Three-dimensional Versus Two-dimensional Laparoscopic Surgery for Colorectal Cancer: Systematic Review and Meta-analysis.

Authors:  George Pantalos; Dimitrios Patsouras; Eleftherios Spartalis; Dimitrios Dimitroulis; Gerasimos Tsourouflis; Nikolaos Nikiteas
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

8.  Association of Surgical Skill Assessment With Clinical Outcomes in Cancer Surgery.

Authors:  Nathan J Curtis; Jake D Foster; Danilo Miskovic; Chris S B Brown; Peter J Hewett; Sarah Abbott; George B Hanna; Andrew R L Stevenson; Nader K Francis
Journal:  JAMA Surg       Date:  2020-07-01       Impact factor: 14.766

9.  What's the magic number? Impact of time to initiation of treatment for rectal cancer.

Authors:  Gretchen C Edwards; Adriana C Gamboa; Michael P Feng; Roberta L Muldoon; Michael B Hopkins; Sherif Abdel-Misih; Glen C Balch; Jennifer Holder-Murray; Maryam Mohammed; Scott E Regenbogen; Matthew L Silviera; Alexander T Hawkins
Journal:  Surgery       Date:  2021-09-24       Impact factor: 4.348

10.  Three-year outcome after transanal versus laparoscopic total mesorectal excision in locally advanced rectal cancer: a multicenter comparative analysis.

Authors:  F B de Lacy; S X Roodbeen; J Ríos; J van Laarhoven; A Otero-Piñeiro; R Bravo; T Visser; R van Poppel; S Valverde; R Hompes; C Sietses; A Castells; W A Bemelman; P J Tanis; A M Lacy
Journal:  BMC Cancer       Date:  2020-07-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.